Science

Since his days as head of the Solar Energy Research Institute under President Jimmy Carter, Denis Hayes has been pushing to add more renewable energy sources to the country's energy portfolio. Hayes discusses the current U.S. market for renewables such as solar and wind, and gives his take on where he sees America's energy future headed.

Transcript

IRA FLATOW, HOST:

Think for a minute about the victims of climate change. You might envision the polar bear, right? You see a lot of that in the news, atop a block of melting ice or - where there's no ice to grab onto, or the great ice sheet covering Greenland drip, drip, dripping away, or the tiny island of Tuvalu whose people and beaches might soon be swallowed by rising seas.

Transcript

IRA FLATOW, HOST:

Up next, Flora Lichtman is here with us for our Video Pick of the Week. Hi, Flora.

FLORA LICHTMAN, BYLINE: Hi, Ira.

You went with something Seattlely(ph). How would I describe it - Seattle-like this week for this week's video.

That's right. When in Mayor McSchwinn's city, you have to go with the bikes. Lightening it up for pick of the week, but - as usual.

(LAUGHTER)

LICHTMAN: Oh, yes. This week's video is about, not just any bicycle builders, these are folks who are building bicycles out of bamboo.

Transcript

NEAL CONAN, HOST:

This is TALK OF THE NATION. I'm Neal Conan.

We've all seen a flock of birds shift direction instantaneously mid-flight, or a school of fish swirl in what looked like tightly choreographed maneuvers. That's called collective behavior and it fascinated and baffled scientists. Why do they do it? How? Telepathy? Now technology is revolutionizing the way researchers can track, visualize and even create swarms, and what they're finding will make you go wow.

A trio of Chinese astronauts has successfully docked with the Tiangong-1 space laboratory for what's expected to be a total of 15 days in orbit — the longest mission to date for China's burgeoning manned space program.

A once-a-day pill has been proven to lower the risk of getting HIV among needle-using drug addicts, just as it does among heterosexual couples and men who have sex with men.

Among 2,400 injecting drug users in Bangkok, those assigned to take a daily dose of an antiviral drug Viread, or tenofovir generically, had half the risk of getting HIV over a four-year period as those who took a placebo pill. Among those who took tenofovir faithfully, there were 74 percent fewer infections.